ASCPT Journal Family’s Post

This an excellent analysis.

HFS-TB: on i. standardization of experiments, ii. aspects to be considered when reporting novel results, iii. critical parameters currently overlooked. https://lnkd.in/eScsw5dp

There are so many reports of new TPD agents reported these days supported by datasets ranging from comprehensive to "questionable", I thought I'd suggest some pointers to generate a simple 3 part dataset which will help us all sort the well-behaved degraders from others which may have profiles more complex than meets the eye. Inspired by an excellent recent article from Ingo Hartung and colleagues, I hope those in the field find it of use. Read more on my blog. https://lnkd.in/eZka29Jc

Thanks for highlighting our paper, Ian. The web page you are building is a great source for information in this fast moving space!

Learn all about BMR https://lnkd.in/d4PCre8e

Next steps https://lnkd.in/gYF2BeF9

Abstract: Targeting the programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway has evolved into one of the most promising strategies for tumor immunotherapy. Thus far, multiple monoclonal antibody drugs have been approved for treating a variety of tumors, while the development of small-molecule PD-1/PD-L1 inhibitors has lagged far behind, with only a few small-molecule inhibitors entering clinical trials. In addition to antibody drugs and small-molecule inhibitors, reducing the expression levels of PD-L1 has attracted extensive research interest as another promising strategy to target the PD-1/PD-L1 pathway. Herein, we analyze the structures and mechanisms of molecules that reduce PD-L1 expression and classify them as degraders and downregulators according to whether they directly bind to PD-L1. Moreover, we discuss the potential prospects for developing PD-L1-targeting drugs based on these molecules. It is hoped that this perspective will provide profound insights into the discovery of potent antitumor immunity drugs. https://lnkd.in/g8VbKGXd - |#drugdevelopment #science #medicinalchemistry #drugdiscovery #medicine #drugspharmaceuticals #oncology #drug

Good summary of an important article! https://lnkd.in/e9kvNR5X https://lnkd.in/erxBfqGN

Synensys was awarded a research contract by The U.S. Food and Drug Administration (FDA) to conduct the study “Improving the Reliability, Interoperability, Agility, and Quality of Laboratory Data Exchanges using System Safety Engineering Methods” under an FDA Broad Agency Agreement. With over 13 billion laboratory tests performed across the U.S. each year, patients, providers, public health officials, and researchers depend on reliable laboratory data to diagnose, treat, prevent, and manage disease, especially during the COVID-19 pandemic. Synensys and their project team, including experts from the Massachusetts Institute of Technology, the University of Nebraska Medical Center, the College of American Pathologists, Deloitte Consulting, LLP, and JP Systems applied safety engineering methods to assess, measure, document, and analyze the safety and quality of the U.S. laboratory data ecosystem. Our research team used the System Theoretic Process Analysis (STPA) methodology to proactively identify and highlight systemic safety flaws and opportunities for future system redesign. Click the link below to read the Project Overview, Executive Summary and the Full Report: https://lnkd.in/e9Vv6Wsh

Learn all about BMR https://lnkd.in/dsrkapgY